Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394612 | 0.82 | — | — | |
| SCHEMBL4956296 | 0.79 | KDM4E (0.39) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL18901740 | 0.79 | RNPEP (0.34) | — | |
| SCHEMBL4954061 | 0.78 | ADH1B (0.32) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL4953275 | 0.78 | CYP2C9 (0.39) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL4949608 | 0.76 | CHRM1 (0.30) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL4956990 | 0.76 | HDAC3 (0.39) | HDAC1HDAC2MAPK1 | |
| SCHEMBL4954174 | 0.75 | TP53 (0.34) | — | |
| SCHEMBL4952995 | 0.75 | ACE (0.32) | — | |
| SCHEMBL18944755 | 0.74 | ALDH1A1 (0.50) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560558-B1 | USE OF 3-POSITION CYCLOSPORIN DERIVATIVES FOR HAIR GROWTH | LG HOUSEHOLD & HEALTH CARE LTD (KR) | 2010-12-29 | — | — | EP | claimed |
| EP-1560558-A4 | USE OF 3-POSITION CYCLOSPORIN DERIVATIVES FOR HAIR GROWTH | LG HOUSEHOLD & HEALTH CARE LTD (KR) | 2008-09-24 | — | — | EP | claimed |
| JP-2006508103-A | — | — | 2006-03-09 | — | — | JP | claimed |
| US-6987090-B2 | Use of 3-position cyclosporin derivatives for hair growth | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2006-01-17 | — | — | US | claimed |
| EP-1560558-A1 | USE OF 3-POSITION CYCLOSPORIN DERIVATIVES FOR HAIR GROWTH | LG Household & Health Care Ltd. (KR) | 2005-08-10 | — | — | EP | claimed |
| WO-2004041221-A1 | USE OF 3-POSITION CYCLOSPORIN DERIVATIVES FOR HAIR GROWTH | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2004-05-21 | — | — | WO | claimed |
| US-20040087496-A1 | Use of 3-position cyclosporin derivatives for hair growth | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2004-05-06 | — | — | US | claimed |
| EP-1560558-B1 | USE OF 3-POSITION CYCLOSPORIN DERIVATIVES FOR HAIR GROWTH | LG HOUSEHOLD & HEALTH CARE LTD (KR) | 2010-12-29 | — | — | EP | disclosed |
| EP-1560558-A4 | USE OF 3-POSITION CYCLOSPORIN DERIVATIVES FOR HAIR GROWTH | LG HOUSEHOLD & HEALTH CARE LTD (KR) | 2008-09-24 | — | — | EP | disclosed |
| US-6987090-B2 | Use of 3-position cyclosporin derivatives for hair growth | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2006-01-17 | — | — | US | disclosed |
| EP-1560558-A1 | USE OF 3-POSITION CYCLOSPORIN DERIVATIVES FOR HAIR GROWTH | LG Household & Health Care Ltd. (KR) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004041221-A1 | USE OF 3-POSITION CYCLOSPORIN DERIVATIVES FOR HAIR GROWTH | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2004-05-21 | — | — | WO | disclosed |
| US-20040087496-A1 | Use of 3-position cyclosporin derivatives for hair growth | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087496-A1 | Use of 3-position cyclosporin derivatives for hair growth | TPMT, BHMT2, SUCLG1 | TDP1 2868/4885CHRM1 4879/4885AKR1A1 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.